BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
BioAge Labs, Inc.NASDAQ: BIOA
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital declines year over year
Q1 FY2026 change in working capital of $5.99M (cash outflow) fell 20.4% year over year, ahead of the -223.3% change in trailing-twelve-month change in working capital. Sequentially, it rose 60.4% from the prior quarter.
Context
- Change in working capital amounted to 131.5% of revenue in FY2025.
- Change in working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -20.4% holds above the trailing-twelve-month pace of -223.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (11.83M) USD
- Year-over-year change
- -205.8%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.83M) | -205.8% |
| FY2024 | 2024-12-31 | 11.18M | +66.6% |
| FY2023 | 2023-12-31 | 6.71M | +744.0% |
| FY2022 | 2022-12-31 | 795K | — |
Change in Working Capital vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -223.3% is the 7th highest of 9, against a peer median of +129.7%.
- Change in working capital amounts to 99.7% of revenue for BIOA, versus a peer median of 6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $50.69M USD | -411.7% | — | 131.0% | |
| LTM Mar 2026 | CA$20.24M CAD | +163.3% | -29.5% | 6.5% | |
| LTM Mar 2026 | $15.79M USD | +1014.2% | — | — | |
| LTM Mar 2026 | $15.14M USD | +208.6% | — | 750.8% | |
| LTM Mar 2026 | $13.89M USD | +159.9% | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $10.29M USD | -223.3% | — | 99.7% |
| LTM Mar 2026 | CA$9.2M CAD | -176.3% | -28.4% | 3.0% | |
| LTM Mar 2026 | $6.7M USD | -348.8% | -55.5% | — | |
| LTM Mar 2026 | $2.38M USD | +99.5% | -28.5% | 5.7% | |
| LTM Mar 2026 | $1.35M USD | — | +14.8% | 1.0% | |
| Peer median (excluding BIOA) | — | +129.7% | -28.5% | 6.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.